



IMMUNOTOPE

## **Immunotope, Inc. Receives NIAID Grant Funding for Dengue Virus Vaccine Development**

DOYLESTOWN PA (June 5, 2007) – Today Immunotope Inc announced that it has received grant funding from the National Institute of Allergy and Infectious Diseases to study the human immune response to Dengue Virus infection as the basis for developing a new and effective vaccine against this pathogen. NIAID has classified the Dengue Virus as a Category A Priority due to concern about its potential use as a bioterrorism organism.

"We are very pleased to receive our first funding for the study of an infectious disease," said Ramila Philip, Ph.D., Immunotope President and Chief Scientific Officer. "This award is an important validation of our immunoproteomics platform and infectious disease vaccine discovery and development strategy".

### **About Dengue Virus**

Each year between 50 and 100 million cases of mosquito-borne Dengue Fever and 250,000 to 500,000 cases of its more severe form, Dengue Hemorrhagic Fever, create a significant public health problem in tropical and subtropical regions of the world, including the United States. Persons infected with any one of the four serotypes develop immunity against that serotype; however, a second infection with a different serotype frequently leads to more serious and fatal disease. No vaccines are currently available to protect against re-infection with a different serotype. Immunotope will use its proprietary immunoproteomics technology to develop a vaccine that is protective against infection and re-infection by all four viral serotypes.

### **About Immunotope, Inc.**

Immunotope is a clinical stage biotechnology company developing immunotherapy products for the treatment of cancer and chronic viral infections. Immunotope's comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at its earliest stages and to provide effective treatments that destroy tumors and prevent recurrence and metastasis. The company's lead product, the IMT-1012 multivalent therapeutic vaccine is now being evaluated in a Phase I clinical trial at the Duke University Comprehensive Cancer Center in advanced-stage ovarian and breast cancer patients. Immunotope's viral immunotherapy program is centered on vaccines for the treatment and prevention of chronic hepatitis, influenza and HIV. Immunotope is also developing autoantibody-based tests for early diagnosis of ovarian and prostate cancer. [www.immunotope.com](http://www.immunotope.com)

###

Contacts:

Immunotope, Inc.: Lorraine Keller, Ph.D., Executive Vice President 215-589-6352 or [lkeller@immunotope.com](mailto:lkeller@immunotope.com)

Gregory Tiberend, Richard Lewis Communications, Inc. 212- 827-0020 or [gtiberend@rlcinc.com](mailto:gtiberend@rlcinc.com)